Tag: Alzheimer’s disease

  • Axsome Stock Up Big on Encouraging Alzheimer’s News

    Axsome Stock Up Big on Encouraging Alzheimer’s News

    Shares of Axsome Therapeutics (AXSM) were up about 32% on a volume spike to 10.65 million shares, as compared to daily average volume of 1.28 million shares. All after the company’s “AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes…

  • Biogen Explodes on Game-Changing Alzheimer’s News

    Biogen Explodes on Game-Changing Alzheimer’s News

    Shares of Biogen (BBIB) are up more than $93 in pre-market. All after a substantial announcement on its Alzheimer’s drug study, in partnership with Eisai. In fact, “The two pharma companies said their drug lecanemab reduced cognitive and functional decline by 27% relative to a placebo. The findings come over an 18 month stretch in…

  • Crisis and Opportunity: Cassava Sciences Still a Strong Buy

    Crisis and Opportunity: Cassava Sciences Still a Strong Buy

    “With SAVA, once the pullback has exhausted itself, it’s a strong buy,” we noted on July 29. Since bottoming out around $65, the stock is back to $86.20 – and could refill its bearish gap around $140 with patience.  In fact, if the company can continue to progress with its Alzheimer’s treatment, this stock could…

  • This is Why Cassava Sciences is Exploding Even Higher

    This is Why Cassava Sciences is Exploding Even Higher

    Cassava Sciences (SAVA) is one of the hottest stocks on the market. Since mentioning it yesterday, the stock has now run from $108 to $126.48. From here, it could see higher highs, as we near its presentation at the 2021 Alzheimer’s Association International Conference on July 26.  The presentations will include “Cassava Sciences’ investigational product…